A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Latest Information Update: 05 Jul 2025
At a glance
- Drugs ML 007/muscarinic antagonist (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
Most Recent Events
- 05 Jul 2025 New trial record